Turbine and Daiichi Sankyo Expand ADC Discovery Collaboration
LONDON, UK and BUDAPEST, HUNGARY – September 24, 2026 – Turbine, a leading virtual biology company, today announced the expansion of its collaboration with Daiichi Sankyo following the successful completion of an initial feasibility program evaluating Turbine’s predictive modeling capabilities for ADC development. The parties will use Turbine’s virtual biology platform vLab® to run Virtual Assays (computational experiments that simulate biological responses across large numbers of conditions) to accelerate and de-risk Daiichi Sankyo’s ADC discovery programs. The collaboration also establishes a foundation for iterative learning, where simulated experiments guide efficient data generation, and experimental validation feeds back into ever-improving computational models. Every lab-in-the-loop cycle sharpens Virtual Assays further, creating a compounding learning effect as new experimental data strengthens the knowledge base informing subsequent predictions and decisions across ADC discovery.
The initial feasibility program built a foundation of trust in Turbine’s predictive modeling approach, demonstrating its ability to generate meaningful insights relevant to ADC research and development. The results provided confidence to expand the collaboration, with Turbine’s vLab® platform now being applied to Daiichi Sankyo’s proprietary ADC programs to explore complex biology and support data-driven decision-making across ADC discovery.
As ADC pipelines grow, selecting the optimal payload, combination, indication and biomarker strategies has become a significant challenge in oncology R&D, particularly as novel payload classes introduce new complexity. Traditional experimental approaches can address only a fraction of the enormous biological search space required to optimize these decisions. Turbine’s vLab® addresses this challenge by enabling scientists to simulate experiments at computational scale, identify hypotheses supported by mechanistic evidence, and prioritize the most promising candidates for experimental validation. Turbine’s ‘lab without limits’ is an easy-to-use, no-code platform with collaborative workflows and interactive visualizations. The resulting in silico data packages can be integrated into existing R&D processes to accelerate decision-making.
“Virtual Assays offer near infinite search space and greatly reduce the number of wet lab experiments needed. We believe in silico experimentation will become the prerequisite for wet lab work and the accelerant across R&D pipelines, transforming R&D productivity,” said Szabolcs Nagy, Chief Executive Officer and Co-Founder of Turbine. “With vLab®, we’ve already worked with partners including AstraZeneca and MSD (Merck & Co.) to generate mechanistic insights and prioritize targets and biomarkers in defined patient populations. This collaboration reflects Turbine and Daiichi Sankyo’s shared commitment to applying innovation to improve decision-making across ADC discovery. We are excited to expand the collaboration into Daiichi Sankyo’s proprietary programs and combine its data and ADC expertise with Turbine’s vLab platform to accelerate the discovery of novel cancer therapies.”
About Turbine
A lab without limits, built for biopharma. Turbine’s Virtual Lab (vLab®) enables scientists to run Virtual Assays across millions of biological conditions far beyond traditional laboratory throughput. Instead of narrowing hypotheses to fit experimental constraints, scientists can explore the broader biological search space computationally before deciding what to validate in the wet lab. Turbine doesn’t replace the wet lab. It makes every experiment count. Through an integrated lab-in-the-loop workflow, virtual findings become testable hypotheses, with validation results feeding back to strengthen subsequent predictions within the workflow. In deployed programs, Turbine has reduced decision timelines from 12–18 months to approximately two months while cutting wet-lab experiments by more than 50%. For more information, please visit www.turbine.ai.
About Daiichi Sankyo
Daiichi Sankyo (TSE: 4568) is a global healthcare company committed to becoming a trusted healthcare innovator, transforming the lives of people through its strength in science and technology. The company discovers and develops new standards of care to address diverse medical needs to fulfill its purpose of contributing to the enrichment of quality of life around the world. With a strategic focus on oncology, Daiichi Sankyo is advancing an industry-leading antibody drug conjugate portfolio along with identifying new breakthrough generating technologies to deliver practice-changing medicines to patients, healthcare professionals and society. For more information, please visit www.daiichisankyo.com.
About the ADC Portfolio of Daiichi Sankyo
The Daiichi Sankyo ADC portfolio consists of eight ADCs in clinical development crafted from ADC technology discovered in-house by Daiichi Sankyo.
The DXd ADC Technology platform of Daiichi Sankyo consists of seven ADCs in clinical development where each ADC is comprised of a monoclonal antibody attached to a number of topoisomerase I inhibitor payloads (an exatecan derivative, DXd) via tetrapeptide-based cleavable linkers. The DXd ADCs include Enhertu and Datroway, which are being jointly developed and commercialized globally with AstraZeneca, and ifinatamab deruxtecan (IDXd), raludotatug deruxtecan (R-DXd) and patritumab deruxtecan (HER3-DXd), which are being jointly developed and commercialized globally with Merck & Co., Inc, Rahway, NJ, USA. DS-3939 and DS3790 are being developed by Daiichi Sankyo.
An additional ADC being developed by Daiichi Sankyo is DS3610, which consists of an antibody attached to a novel payload that acts as an agonist of STING.
Ifinatamab deruxtecan, raludotatug deruxtecan, patritumab deruxtecan, DS-3939, DS3610 and DS3790 are investigational medicines that have not been approved for any indication in any country. Safety and efficacy have not been established.